Prothena Corporation plc · NASDAQ:PRTA

Prothena — Technical Presentation (March 2020)

12 slides from Prothena's technical presentation, Mar 27, 2020

  1. Slide 1: Disclosure of relationships

    No, nothing to disclose ü Yes, please specify: Consulting/ Ownership/ Other Company/ Honoraria/ Advisory Funded Royalties/ Stock Equity (please Name Expenses boards research Patent options position Employee specify) Roche/ G Pagano ü 1

  2. Slide 2: A Phase 2 study of prasinezumab in early Parkinson's disease (PASADENA)

    A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): Rationale, design and baseline data Gennaro Pagano,1* F Boess,1 K.I Taylor,1,2 B Mollenhauer,3,4 W Poewe,5 M Marchesi,1 A Boulay,1 J Anzures-Cabrera,6 A Vogt,1 T Nikolcheva,7 W Zago,8 R Tripu

  3. Slide 3: MoA of prasinezumab

    MoA of prasinezumab • a-synuclein is genetically and neuropathologically validated as a key target in PD1,2 • Prasinezumab is a humanised IgG1 monoclonal antibody that binds aggregated Extracellular a-synuclein with higher selectivity over aggregated a-synuclein monomeric a-synuclein3–7 Synaptic los

  4. Slide 4: PASADENA Phase 2 study design

    PASADENA Phase 2 study design • 316 participants with early PD • Key inclusion criteria: Part 1 Part 2 • age 40–80 years • diagnosis: bradykinesia and Prasinezumab IV Q4W rigidity and/or resting tremor . Low dose* • disease duration ≤ 2 years . • H&Y Stage I–II, MMSE >25 Placebo IV Q4W . . Prasinezu

  5. Slide 5: Primary and secondary endpoints

    Primary and secondary endpoints Primary • Change from baseline to Week 52 in total MDS-UPDRS (sum of Parts I, II and III)* Secondary • Change from baseline to Week 52 in the following: – MDS-UPDRS Part I non-motor aspects and MDS-UPDRS Part II motor aspects of experiences of daily living – MDS-UPDRS

  6. Slide 6: Schedule of activities in PASADENA Part 1

    Schedule of activities in PASADENA Part 1 Screening Baseline Week 8 Week 16 Week 24 Week 32 Week 40 Week 48 Week 52 MDS-UPDRS MoCA CGI-C PGI-C SE-ADL PDQ39** SCOPA-AUT† PDSS-2 DaT-SPECT Digital* Only at screening: CGI-S, mH&Y, MMSE, RBDQ *Digital includes digital motor score, PGI-S , Daily diary, Pa

  7. Slide 7: Schedule of activities in PASADENA Part 2

    Schedule of activities in PASADENA Part 2 Withdrawal Week 56 Week 64 Week 72 Week 80 Week 88 Week 96 Week 100 Week 104 3 months MDS-UPDRS MoCA CGI-C PGI-C SE-ADL PDQ39** SCOPA-AUT† PDSS-2 DaT-SPECT Digital* Only at screening: CGI-S, mH&Y, MMSE, RBDQ *Digital includes digital motor score, PGI-S , Dai

  8. Slide 8: Roche Parkinson's Disease Mobile Application V2

    Roche Parkinson’s Disease Mobile Application V2 High adherence Test-retest reliabilities Clinical relationship Active tests performed 5–6/7 days ‘Excellent’ for all active tests Exemplified with rest tremor; all other active tests significant (P£0.001) Average Movement Energy (log) aggregated over 2

  9. Slide 9: Baseline data (1/2)

    UNPUBLISHED DATA – DO NOT COPY OR DISTRIBUTE Baseline data (1/2) PPMI PASADENA PASADENA PASADENA PASADENA-like All patients patients on MAO-Bi drug-naive patients PD patients* (n=316) (n=115) (n=201) (n=337) Age, years Mean (SD) 59.9 (9.1) 58.2 (9.0) 60.8 (9.0) 61.3 (9.7) Gender Male 213 (67.4%) 74

  10. Slide 10: Baseline data (2/2)

    UNPUBLISHED DATA – DO NOT COPY OR DISTRIBUTE Baseline data (2/2) PPMI PASADENA PASADENA PASADENA PASADENA-like All patients patients on MAO-Bi drug-naive patients PD patients* (n=316) (n=115) (n=201) (n=337) MDS-UPDRS Part I Mean (SD) 4.6 (3.8) 4.5 (3.4) 4.7 (4.1) 5.6 (3.9) MoCA Mean (SD) 27.9 (2.0)

  11. Slide 11: Conclusion

    UNPUBLISHED DATA – DO NOT COPY OR DISTRIBUTE Conclusion The PASADENA study was designed using the PPMI population as reference, and also includes patients receiving MAO-Bi The PASADENA population has: • a similar motor symptom severity as the PPMI population, regardless of the inclusion of patients

  12. Slide 12: Thank you!

    Thank you! We thank all participants and their families, the PASADENA investigators and the Prasinezumab Study Group for their cooperation and support with this study PASADENA investigators: Jean-Philippe Azulay, Ernest Balaguer Martinez, James Boyd, Matthew Brodsky, Anthony Ciabarra, Joseph Classen

Prothena — Technical Presentation (March 2020) on 6ix